Circulating Tumor Cell Market Research Report- Global Forecast to 2023

Circulating Tumor Cell (CTC) Market Share, Growth and Trends Analysis By Application (Research, Drug Development), Technology (CTC Enrichment, CTC Detection), End-User (Hospital & Clinics, Research & Academic Institutes, Diagnostic Centers) - Global Forecast Till 2023

ID: MRFR/Pharma/0854-CR | August 2018 | Region: Global | 110 pages

Circulating Tumor Cell Market Overview


In 2017, the global market size of circulating tumor cell (CTC) reached a valuation of USD 9,393.1 Mn. The market is projected to surpass a valuation of USD 28,300 Mn by the end of 2023, reflecting a healthy growth rate. The prevalence rate of CTC has gone up in recent years. The mechanism of CTC is responsible for a vast majority of deaths caused by cancer. Significant progress has been made in developing effective CTC diagnostics and treatment, though, survival rates remain moderate. Circulating tumor cells can be associated with different types of cancer prognosis including breast cancer, prostate cancer, and gastric cancer among others. Healthcare companies continue to focus on developing solutions that enable accurate and quick detection of CTC. The diagnosis and analysis of CTCs can help in early cancer detection and determine appropriate treatments tailored for specific cancer types.


Report Overview


This MRFR report offers a full-fledged analysis of the global market for circulating tumor cells. It also discuses the market opportunities for biomarkers active in the particular class as well as identifies the existing challenges. The primary objective of the report is to provide a five-year (2018-2023) revenue assessment of the global CTC market. MRFR’s report holds a fair perspective towards the CTC market and explores the application scope of the existing CTC technologies in clinical, research and drug development activities. The research document also profiled CTC technologies that are currently available, which include CTC Enrichment, CTC Detection and Combined Enrichment and Separation of CTC (CTC analysis). Revenue analysis on the basis of major end users of CTC technology covers hospital & clinics, research & academic institutes and diagnostic centers. The report undertakes a market study on a global level, which covers South America, North America, Asia Pacific (APAC), the Middle East & Africa (MEA) and Europe.


Report Coverage


Value, Market Share, Player Analysis, value chain analysis, Porter's five forces model, demand & supply: gap analysis, investment opportunities analysis, pricing analysis, technological trends, country level break down for services segment.


Circulating Tumor Market Companies Profiled


Ikonisys Inc., Greiner Bio-One International GmbH, Thermo Fisher Scientific, SRI International, STEMCELL Technologies, Miltenyi Biotec, Menarini Silicon Biosystems, QIAGEN Hannover (QIAGEN), F. Hoffmann-La Roche Ltd, NanoString Technologies, Inc, Fluxion Biosciences, Inc., GE Healthcare, ApoCell, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), Epic Lifesciences, Celltraffix Inc.


Research Methodology


Market Research Future (MRFR) leverages its vast repository of market data along with fail-safe statistical tools for delivering accurate foresight. Market outcomes are derived through extensive primary research. Primary data collected is verified by secondary research from credible sources such as SEC filings, whitepaper references, paid database services, annual reports, and research publication by national and international organizations among others. Robust analytical algorithms are employed for mapping data and drawing impactful insight into the market. Top-down and bottom-up approaches are engaged for accurate estimation of the market size and revenue. A multi-layer verification process evaluated the data points offered in our reports. The aim is to deliver an actionable intelligence supported by graphical representations for enhanced lucidity.


Other Description



  • Market Denomination- USD

  • Base year- 2017

  • Forecast Period- From 2018 to 2023


For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for circulating tumor cell


By Application


  • Clinical

  • Research

  • Drug Development


By Technology 


  • CTC Enrichment

  • CTC Detection

  • Combined Enrichment and Separation of CTC (CTC analysis)


By End-User



  • Hospital & Clinics

  • Research & Academic Institutes

  • Diagnostic Centers


BY Region



  • Americas

  • North America

    • S

    • Canada



  • South America

  • Europe

  • Western Europe

    • Germany

    • K

    • France

    • Spain

    • Italy

    • Rest of Western Europe



  • Eastern Europe

  • Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia Pacific

  • Middle East & Africa

  • Middle East

  • Africa


Intended Audience



  • Hospitals and clinics

  • Research institutes

  • Pharmaceutical & Bioterchnology Industries

  • Suppliers and distributors

  • Potential investors

  • Raw material suppliers

  • Government Associations



Frequently Asked Questions (FAQ) :


Global Circulating Tumor Cell Market is expected to touch a valuation of USD 28,300 million by 2023.

Global Circulating Tumor Cell Market stood at USD 9,393.1 million in 2017.

Global Circulating Tumor Cell Market can expand at a CAGR of 20.32% from 2018 to 2023.

Hospitals & clinics are predicted to be the biggest end-use segment of the Global Circulating Tumor Cell Market.

Americas can dominate the Global Circulating Tumor Cell Market.

ApoCell, F. Hoffmann-La Roche Ltd, Celltraffix Inc., QIAGEN Hannover (QIAGEN), STEMCELL Technologies, Thermo Fisher Scientific, Greiner Bio-One International GmbH, SRI International, GE Healthcare, Ikonisys Inc., NanoString Technologies, Inc, Fluxion Biosciences, Inc., Miltenyi Biotec, Menarini Silicon Biosystems, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), and Epic Lifesciences are the major players of the Global Circulating Tumor Cell Market.

The global circulating tumor cell market was valued at USD 9393.1 Million in 2017 and is expected to attain USD 28,399.2 Million by the end of 2023. Factors such as growing prevalence of cancer, increasing research and development activities, advances in biomedical and bioengineering technology and rise in global geriatric population are factors which will shape the global circulating tumor cell market and help it attain a CAGR of 20.32% over the forecast period of 2018-2023.


Circulating tumor cells find their application in cancer diagnostics and management and growing incidences of oncology diseases boost the growth of the global circulatory tumor cells market. CTCs are used as a biomarker for early detection of cancer; they act as an indicator of treatment response and are beneficial in predicting outcomes and prognostication in cancer management.


Persistent need for treatment of various chronic diseases prompts vast investments by the pharmaceutical and biotechnology sector on research and development to develop breakthrough therapies for cancer and other chronic illnesses which is fostering the growth of the global circulating tumor cells market.


CTC tests are expensive as they combine a number of enrichment and detection steps which require various systems, assays, instruments and test kits that hinder the growth of the market.


Huge unmet medical needs in developing regions and a severe lack of proper medical facilities in weak economies challenge the growth of the market, however developing economies offer a high potential for growth opportunities for the global circulatory tumor cell market as it provides room for market growth in the untapped regions. Vendors can achieve growth by marking their presence in such regions by addressing the healthcare challenges.


The global circulatory tumor cells market has been segmented based on application, technology, and end-user. By application, the market has been segmented into clinical, research, drug development, and others. The clinical segment is the largest segment and accounts for 63% of the share. The clinical segment is further segmented into clinical prognostic, diagnosis and management of tumor malignancies, and drug decision. The clinical segment was valued at USD 5,920.9 million in 2017 and is expected to reach USD 18,225.8 million by the end of 2023.  The drug development segment is expected to exhibit sturdy growth over the forecast period as pharmaceutical and biotech companies are increasingly focusing on CTC for drug development.


By technology, the market has been segmented into CTC enrichment, CTC detection, and CTC analysis. Technology-wise, CTC enrichment is the largest segment owing to its effectiveness in reduction of time needed for isolation of rare CTCs.


By end-user, the market has been segmented into hospitals and clinics, research and academic institutes, diagnostic centers, and others. Hospitals and clinics segment dominates the global market and is expected to attain USD 9,184.9 million by the end of 2023. There has been an incessant need for diagnosis and treatment of cancer which will help the hospitals and clinics segment grow at an impressive CAGR of 20.92% over the forecast period.


Regional Analysis


The global circulatory tumor cell market spans across the regions of the Americas, Europe, Asia Pacific and the Middle East & Africa. Globally, the Americas account for the largest share of the circulating tumor cell market owing to the high prevalence of cancer in the region. Moreover, the Americas have a robust healthcare sector and is an early adopter of new technologies for healthcare purposes which drives the market in the region. The America market for circulating tumor cell is expected to reach USD 13,011.5 Million by the end of 2023 and expand at a CAGR of 20.56% over the forecast period.


Europe is the second largest market for circulating tumor cells and is closely followed by Asia Pacific. Asia Pacific market is mushrooming in size and is expected to expand at a CAGR of 20.84% over the forecast period. The untapped markets of Asia Pacific store high growth opportunities for the global market. Rising incidences of cancer along with technological advancements favor the growth of the market in the region.


Competitive Tracking


The global circulating tumor cells market is a highly competitive one with the presence of a multitude of local as well as regional players. The market players are pouring in money for R&D and are competing based on cost, quality, and reliability. The notable players in the global circulating tumor cell market include Greiner Bio-One International GmbH, Thermo Fisher Scientific,  STEMCELL Technologies, Menarini Silicon Biosystems, F. Hoffmann-La Roche Ltd,  Fluxion Biosciences, Inc., Ikonisys Inc., SRI International, Miltenyi Biotec, QIAGEN Hannover (QIAGEN), and NanoString Technologies, Inc.


 

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

USD YEN EURO GBP INR
TABLE OF CONTENT

2.1 Assumptions & Limitations 16

3.1 Research Process 19

3.2 Primary Research 19

3.3 Secondary Research 19

3.4 Market Size Estimation 20

4.1 Introduction 22

4.2 Drivers 22

4.2.1 Rising occurrence of cancer 22

4.2.2 Increasing research and development 22

4.2.3 Rising geriatric population 23

4.3 Restraint 23

4.3.1 High cost of CTC tests and instruments 23

4.4 Opportunity 23

4.4.1 Entering developing economies 23

5.1 Value Chain Analysis 25

5.1.1 R&D and Designing 25

5.1.2 Manufacturing 25

5.1.3 Distribution & Sales 26

5.1.4 Post-Sales Review 26

5.2 Porter’s Five Forces Model 26

5.2.1 Bargaining Power of Suppliers 27

5.2.2 Bargaining Power of Buyers 27

5.2.3 Threat of New Entrants 27

5.2.4 Threat of Substitutes 27

5.2.5 Intensity of Rivalry 27

6.1 Introduction 29

6.2 Clinical 30

6.3 Research 30

6.4 Drug Development 31

7.1 Introduction 33

7.2 CTC Enrichment 34

7.3 CTC Detection 34

7.4 Combined Enrichment and Separation of CTC (CTC analysis) 34

8.1 Introduction 36

8.2 Hospital & Clinics 37

8.3 Research & Academic Institutes 37

8.4 Diagnostic Centers 37

9.1 Introduction 39

9.2 Americas 40

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.2.1 North America 42

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.2.1.1 U.S 44

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.2.1.2 Canada 46

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.2.2 South America 47

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.3 Europe 50

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.3.1 Western Europe 52

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.3.1.1 Germany 54

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.3.1.2 U.K 56

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.3.1.3 France 57

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.3.1.4 Spain 59

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.3.1.5 Italy 61

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.3.1.6 Rest of Western Europe 62

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.3.2 Eastern Europe 64

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.4 Asia Pacific 66

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.4.1 China 68

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.4.2 Japan 70

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.4.3 India 71

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.4.4 Australia 73

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.4.5 Republic of Korea 75

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.4.6 Rest of Asia Pacific 76

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.5 Middle East & Africa 79

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.5.1 Middle East 81

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

9.5.2 Africa 83

Circulating Tumor Cell Market, by Application

Circulating Tumor Cell Market, by Technology

Circulating Tumor Cell Market, by End-User

11.1 Greiner Bio-One International GmbH 88

11.1.1 Company Overview 88

11.1.2 Financial Overview 88

11.1.3 Products Offering 89

11.1.4 Key Developments 89

11.1.5 SWOT Analysis 89

11.1.6 Key Strategy 89

11.2 Ikonisys Inc. 90

11.2.1 Company Overview 90

11.2.2 Financial Overview 90

11.2.3 Products Offering 90

11.2.4 Key Developments 90

11.2.5 SWOT Analysis 90

11.2.6 Key Strategy 90

11.3 Thermo Fisher Scientific 91

11.3.1 Company Overview 91

11.3.2 Financial Overview 91

11.3.3 Products Offering 92

11.3.4 Key Developments 92

11.3.5 SWOT Analysis 92

11.3.6 Key Strategy 92

11.4 SRI International 93

11.4.1 Company Overview 93

11.4.2 Financial Overview 93

11.4.3 Products Offering 93

11.4.4 Key Developments 93

11.4.5 SWOT Analysis 94

11.4.6 Key Strategy 94

11.5 STEMCELL Technologies 95

11.5.1 Company Overview 95

11.5.2 Financial Overview 95

11.5.3 Products Offering 95

11.5.4 Key Developments 95

11.5.5 SWOT Analysis 95

11.5.6 Key Strategy 95

11.6 Miltenyi Biotec 96

11.6.1 Company Overview 96

11.6.2 Financial Overview 96

11.6.3 Products Offering 96

11.6.4 Key Developments 96

11.6.5 SWOT Analysis 96

11.6.6 Key Strategy 97

11.7 Menarini Silicon Biosystems 98

11.7.1 Company Overview 98

11.7.2 Financial Overview 98

11.7.3 Products Offering 98

11.7.4 Key Developments 98

11.7.5 SWOT Analysis 98

11.7.6 Key Strategy 98

11.8 QIAGEN Hannover (QIAGEN) 99

11.8.1 Company Overview 99

11.8.2 Financial Overview 99

11.8.3 Products Offering 99

11.8.4 Key Developments 100

11.8.5 SWOT Analysis 100

11.8.6 Key Strategy 100

11.9 F. Hoffmann-La Roche Ltd 101

11.9.1 Company Overview 101

11.9.2 Financial Overview 101

11.9.3 Products Offering 102

11.9.4 Key Developments 102

11.9.5 SWOT Analysis 102

11.9.6 Key Strategy 102

11.10 NanoString Technologies, Inc. 103

11.10.1 Company Overview 103

11.10.2 Financial Overview 103

11.10.3 Products Offering 103

11.10.4 Key Developments 104

11.10.5 SWOT Analysis 104

11.10.6 Key Strategy 104

11.11 Fluxion Biosciences, Inc. 105

11.11.1 Company Overview 105

11.11.2 Financial Overview 105

11.11.3 Products Offering 105

11.11.4 Key Developments 105

11.11.5 SWOT Analysis 105

11.11.6 Key Strategy 106

11.12 GE Healthcare 107

11.12.1 Company Overview 107

11.12.2 Financial Overview 107

11.12.3 Products Offering 107

11.12.4 Key Developments 108

11.12.5 SWOT Analysis 108

11.12.6 Key Strategy 108

12.1 Discussion Blue Print 110

TABLE 1 GLOBAL CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 29

TABLE 2 GLOBAL CIRCULATING TUMOR CELL MARKET FOR CLINICAL APPLICATION 2015-2023 (USD MILLION) 30

TABLE 3 GLOBAL CIRCULATING TUMOR CELL MARKET FOR RESEARCH APPLICATION 2015-2023 (USD MILLION) 30

TABLE 4 GLOBAL CIRCULATING TUMOR CELL MARKET FOR DRUG DEVELOPMENT APPLICATION 2015-2023 (USD MILLION) 31

TABLE 5 GLOBAL CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 33

TABLE 6 GLOBAL CIRCULATING TUMOR CELL MARKET FOR CTC ENRICHMENT 2015-2023 (USD MILLION) 34

TABLE 7 GLOBAL CIRCULATING TUMOR CELL MARKET FOR CTC DETECTION 2015-2023 (USD MILLION) 34

TABLE 8 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COMBINED ENRICHMENT AND SEPARATION OF CTC (CTC ANALYSIS) 2015-2023 (USD MILLION) 34

TABLE 9 GLOBAL CIRCULATING TUMOR CELL MARKET, BY END-USER 2015-2023 (USD MILLION) 36

TABLE 10 GLOBAL CIRCULATING TUMOR CELL MARKET FOR HOSPITAL & CLINICS 2015-2023 (USD MILLION) 37

TABLE 11 GLOBAL CIRCULATING TUMOR CELL MARKET FOR RESEARCH & ACADEMIC INSTITUTES 2015-2023 (USD MILLION) 37

TABLE 12 GLOBAL CIRCULATING TUMOR CELL MARKET FOR DIAGNOSTIC CENTERS 2015-2023 (USD MILLION) 37

TABLE 13 GLOBAL CIRCULATING TUMOR CELL MARKET, BY REGION 2015-2023 (USD MILLION) 39

TABLE 14 AMERICAS CIRCULATING TUMOR CELL MARKET, BY REGION 2015-2023 (USD MILLION) 40

TABLE 15 AMERICAS CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 41

TABLE 16 AMERICAS CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 41

TABLE 17 AMERICAS CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 41

TABLE 18 AMERICAS CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 42

TABLE 19 AMERICAS CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 42

TABLE 20 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 42

TABLE 21 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 43

TABLE 22 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 43

TABLE 23 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 43

TABLE 24 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 44

TABLE 25 U.S CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 44

TABLE 26 U.S CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 44

TABLE 27 U.S CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 45

TABLE 28 U.S CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 45

TABLE 29 U.S CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 45

TABLE 30 CANADA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 46

TABLE 31 CANADA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 46

TABLE 32 CANADA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 46

TABLE 33 CANADA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 47

TABLE 34 CANADA CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 47

TABLE 35 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 47

TABLE 36 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 48

TABLE 37 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 48

TABLE 38 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 48

TABLE 39 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 49

TABLE 40 EUROPE CIRCULATING TUMOR CELL MARKET, BY REGION 2015-2023 (USD MILLION) 50

TABLE 41 EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 51

TABLE 42 EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 51

TABLE 43 EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 51

TABLE 44 EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 52

TABLE 45 EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 52

TABLE 46 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 52

TABLE 47 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 53

TABLE 48 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 53

TABLE 49 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 53

TABLE 50 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 54

TABLE 51 GERMANY CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 54

TABLE 52 GERMANY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 54

TABLE 53 GERMANY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 55

TABLE 54 GERMANY CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 55

TABLE 55 GERMANY CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 55

TABLE 56 U.K CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 56

TABLE 57 U.K CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 56

TABLE 58 U.K CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 56

TABLE 59 U.K CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 57

TABLE 60 U.K CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 57

TABLE 61 FRANCE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 57

TABLE 62 FRANCE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 58

TABLE 63 FRANCE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 58

TABLE 64 FRANCE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 58

TABLE 65 FRANCE CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 59

TABLE 66 SPAIN CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 59

TABLE 67 SPAIN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 59

TABLE 68 SPAIN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 60

TABLE 69 SPAIN CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 60

TABLE 70 SPAIN CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 60

TABLE 71 ITALY CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 61

TABLE 72 ITALY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 61

TABLE 73 ITALY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 61

TABLE 74 ITALY CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 62

TABLE 75 ITALY CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 62

TABLE 76 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 62

TABLE 77 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 63

TABLE 78 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 63

TABLE 79 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 63

TABLE 80 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 64

TABLE 81 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 64

TABLE 82 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 64

TABLE 83 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 65

TABLE 84 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 65

TABLE 85 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 65

TABLE 86 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY COUNTRY 2015-2023 (USD MILLION) 66

TABLE 87 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 66

TABLE 88 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 67

TABLE 89 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 67

TABLE 90 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 67

TABLE 91 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 68

TABLE 92 CHINA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 68

TABLE 93 CHINA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 68

TABLE 94 CHINA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 69

TABLE 95 CHINA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 69

TABLE 96 CHINA CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 69

TABLE 97 JAPAN CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 70

TABLE 98 JAPAN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 70

TABLE 99 JAPAN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 70

TABLE 100 JAPAN CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 71

TABLE 101 JAPAN CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 71

TABLE 102 INDIA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 71

TABLE 103 INDIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 72

TABLE 104 INDIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 72

TABLE 105 INDIA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 72

TABLE 106 INDIA CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 73

TABLE 107 AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 73

TABLE 108 AUSTRALIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 73

TABLE 109 AUSTRALIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 74

TABLE 110 AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 74

TABLE 111 AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 74

TABLE 112 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 75

TABLE 113 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 75

TABLE 114 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 75

TABLE 115 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 76

TABLE 116 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 76

TABLE 117 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 76

TABLE 118 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 77

TABLE 119 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 77

TABLE 120 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 77

TABLE 121 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 78

TABLE 122 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY REGION 2015-2023 (USD MILLION) 79

TABLE 123 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 79

TABLE 124 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 80

TABLE 125 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 80

TABLE 126 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 80

TABLE 127 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 81

TABLE 128 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 81

TABLE 129 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 81

TABLE 130 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 82

TABLE 131 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 82

TABLE 132 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 82

TABLE 133 AFRICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2015-2023 (USD MILLION) 83

TABLE 134 AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2015-2023 (USD MILLION) 83

TABLE 135 AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR MALIGNANCIES TYPE 2015-2023 (USD MILLION) 83

TABLE 136 AFRICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2015-2023 (USD MILLION) 84

TABLE 137 AFRICA CIRCULATING TUMOR CELL MARKET, BY END USER 2015-2023 (USD MILLION) 84

TABLE 138 TOP MANUFACTURERS IN THE GLOBAL CIRCULATING TUMOR CELLS MARKET 2017 86

FIGURE 1 MARKET STRUCTURE 17

FIGURE 2 RESEARCH PROCESS 19

FIGURE 3 DRO ANALYSIS OF GLOBAL CIRCULATING TUMOR CELL MARKET 22

FIGURE 4 VALUE CHAIN: GLOBAL CIRCULATING TUMOR CELL MARKET 25

FIGURE 5 PORTER’S FIVE FORCES MODEL: GLOBAL CIRCULATING TUMOR CELL MARKET 26

FIGURE 6 GLOBAL CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2017 & 2023 (USD MILLION) 30

FIGURE 7 GLOBAL CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2017 & 2023 (USD MILLION) 33

FIGURE 8 GLOBAL CIRCULATING TUMOR CELL MARKET, BY END-USER 2017 & 2023 (USD MILLION) 36

FIGURE 9 GLOBAL CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2017 (%) 40

FIGURE 10 AMERICAS CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2017 (%) 40

FIGURE 11 EUROPE CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2017 (%) 50

FIGURE 12 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2017 (%) 66

FIGURE 13 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2017 (%) 79

s

Global Circulating Tumor Cells Market: Competitive Landscape


The global circulating tumor cells market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront the market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment.


The growth of the market players is dependent on market conditions, government support, and industry development. Thus, major players should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional players with small market shares also have a presence. International players are likely to strengthen their presence worldwide through acquisitions during the forecast period. It has also been estimated that improvement of the global economic scenario combined with efforts to enhance the infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and increase the global market share.


Players with better technical and financial resources can develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.



  1. Hoffmann-La Roche Ltd has a vast product portfolio in the circulating tumor cells industry. The company also has a wide geographic presence as it operates in various countries across the world. It has a significant presence in North America, Europe, and the Middle East and Africa, with commercial, manufacturing, and research facilities in more than one dozen countries.